London, UK – 9 April 2019 – Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat critical limb ischaemia (CLI), announces today that it will present at upcoming investor and cell therapy conferences over the coming month.
Advanced Therapy Medicinal Products (ATMPs) Investor Day, 10 April, London, UK
Edwin Wagena, Chief Operating Officer will pitch the Rexgenero investment case to an audience of global investors at the UK Advanced Therapy Medicinal Products (ATMPs) Investor Day organized by the Cell and Gene Therapy Catapult. The event will take place in the City of London on the afternoon of Wednesday 10 April. Investor pitches will be intercalated with fireside chats featuring current leaders in the field of cell and gene therapy who will share their experience and perspective on the journey to commercialisation and gaining investment.
The Cell & Gene Meeting on the Mediterranean, 23 – 25 April, Barcelona, Spain
Joe Dupere, CEO of Rexgenero will present an update at the Cell & Gene Meeting on the Med organized by the Alliance for Regenerative Medicine (ARM). Rexgenero’s presentation will take place in the Gaud 2 room at the conference venue at 9.30am on Wednesday 24 April. This meeting is a highlight on the Cell & Gene Therapy conference calendar and features expert-led panels, in-depth keynote speeches, interactive fireside chats, and over fifty presentations by leading publicly traded and privately held companies from around the globe.
Joe will also be attending BioTrinity, 30 April – 1 May, London, UK to network with investors and the pharma industry.
Joe Dupere, CEO of Rexgenero commented, “It is an exciting time as we ramp up patient recruitment at study sites for our Phase III Salamander study of our autologous regenerative therapy for the treatment of critical limb ischaemia. This chronic condition is characterized by chronic ischemic at-rest pain, ulcers, or gangrene in one or both legs. Due to limited efficacy of current treatments, patients have a high risk of amputation and, in the worst cases, death. Our hope is that REX-001 will provide a truly transformative curative option for these patients.”
REX-001, Rexgenero’s lead development candidate, consists of bone marrow-derived mononuclear cells (BM-MNCs) extracted from a patient’s own bone barrow (autologous). It has shown efficacy in up to 80% of patients in Phase II and Phase I/II studies.
Rexgenero is currently recruiting 138 patients at 35 sites in countries across Europe for its Phase III trials of REX-001 for the treatment of critical limb ischaemia in diabetic patients. The trials are called the Salamander study due to the amphibian’s ability to regenerate its tail and limbs.
Rexgenero is a clinical-stage regenerative medicine company developing innovative cell-based therapies targeting serious diseases with unmet medical needs.
The Company’s lead candidate REX-001, is a highly innovative autologous cell therapy that is being studied in a Phase III clinical programme in patients with critical limb ischemia (CLI) with diabetes, a poorly treated disease with a high risk of amputation and death. REX-001 has been shown to be effective in Phase I/II and Phase II trials, alleviating CLI in the majority of patients, offering the potential to increase the quality of life of CLI patients by reducing pain, alleviating ulcers, increasing mobility, improving sleep and reducing the need for amputation. Rexgenero is developing REX-001 in a range of indications and, pending approval, intends to launch and market this specialty product in major territories.
Rexgenero is a privately-owned company, which draws on an exceptional understanding of the fundamental science of cell therapies developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies.
The Company was founded in 2015 and is headquartered in London (UK) with R&D and manufacturing operations in Seville (Spain) and Frankfurt (Germany).
For more information, please visit www.rexgenero.com.
Issued for and on behalf of Immatics by Instinctif Partners.
For more information please contact: Rexgenero@instinctif.com